A life science dedicated PE fund of a Taiwanese company engaged in leasing, finance, and investment businesses is currently seeking new opportunities. The fund prefers to invest in early stage companies but is also interested in growth-expansion stage companies. The fund can invest up to USD 30 million or more per company. The fund will focus on companies founded and operated in the Greater China region (60% of fund allocation). The fund is also interested in opportunities from Europe (especially in Switzerland, Germany, and the UK) as well as from the US.
The fund seeks to invest in biopharmaceuticals and medical technologies. In biopharma, the fund focuses on novel drugs, drugs with new indication/dosage form, biosimilar, and API for cancer drug. The fund looks for proprietary drug discovery or development technologies that are able to build a multi-product pipeline and products that address large unmet medical needs. For medical technologies, the firm focuses on molecular IVD test/next-generation sequencing, monitor & diagnostics system, invasive devices, cosmetics/plastic surgery, ICT medical device, and combination products with Greater China market potential. The firm looks for new and innovative technologies that can increase performance, lower cost or open up new business models.
The fund prefers to invest in early stage companies and generally acquires a minority stake in the company. However, the fund does not rule out the possibilities of acquiring a controlling stake if the strategic value exists.
If you are interested in more information about this investor and other investors tracked by LSN, please email email@example.com